Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 2 1

Status

Enrolling by invitation 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 555Carcinoma, Non-Small-Cell Lung 507Prostatic Neoplasms 330Neoplasms 268Multiple Myeloma 266Colorectal Neoplasms 264Leukemia, Myeloid, Acute 225Squamous Cell Carcinoma of Head and Neck 216Lung Neoplasms 209Neoplasm Metastasis 203Carcinoma, Hepatocellular 195Triple Negative Breast Neoplasms 172Melanoma 172Pancreatic Neoplasms 170Ovarian Neoplasms 150Recurrence 148Lymphoma 143Glioblastoma 134Brain Neoplasms 133Sarcoma 128Leukemia, Lymphocytic, Chronic, B-Cell 127Carcinoma, Renal Cell 127Lymphoma, Large B-Cell, Diffuse 125Stomach Neoplasms 124Head and Neck Neoplasms 120Precursor Cell Lymphoblastic Leukemia-Lymphoma 110Rectal Neoplasms 107Myelodysplastic Syndromes 105Urinary Bladder Neoplasms 100Small Cell Lung Carcinoma 98

Interventions

130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × TNBC × 1 year × Clear all
NCT07376629 2026-01-29

A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC

Huabo Biopharm Co., Ltd.

Phase 2 Enrolling by invitation
60 enrolled
Breast

TNBC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡